The Japanese Patent Office has granted a patent protection for a radiolabelled chemical compound of ammonium salt, designed for MPI (Myocardial Perfusion Imaging) using PET/CT method (cardiotracer).
The Management Board would also like to inform, that the Phase III of the cardiotracer development work is conducted using an active fluorine-labeled molecule for which the Company owns both, exclusive intellectual property and patent protection rights..
The Patent applies to the whole territory of Japan for a period of 20 years from the moment of application, so in this case is valid until 2041.
